Obesity is widely considered a chronic health problem that is often progressive and difficult
to treat. An estimated 80% to 90% of persons with type 2 diabetes are also overweight or …

Objective: To assess treatment responses to sibutramine and weight management in
diabetic patients during the lead‐in period of the Sibutramine Cardiovascular OUTcomes …

OBJECTIVE The Treatment Options for type 2 Diabetes in Adolescents and Youth (TODAY)
trial showed superiority of metformin plus rosiglitazone (M+ R) over metformin alone (M) …

The beneficial effects of weight loss in the obese have been widely accepted. Still, there is a
lack of controlled studies displaying large maintained weight losses over long periods (> 4 …

OBJECTIVE We evaluated the effect of optimizing metformin dosing on glycemia and body
weight in type 2 diabetes. RESEARCH DESIGN AND METHODS This was a prespecified …

Aim: The Sibutramine Cardiovascular OUTcomes trial showed that sibutramine produced
greater mean weight loss than placebo but increased cardiovascular morbidity but not …

Purpose To investigate whether weight change in the first year after initiating an oral
hypoglycemic agent (OHA) for type 2 diabetes treatment is associated with mortality in a …

Obesity is a major risk factor for diabetes and cardiovascular disease, and most people with
diabetes are overweight or obese. Weight reduction has been shown to improve glycemic …

Aims The aim of this study was to assess associations between patient characteristics,
intensification of blood glucose‐lowering treatment through oral glucose‐lowering therapy …

OBJECTIVE We reevaluated the Action for Health in Diabetes (Look AHEAD) intervention,
incorporating diabetes subgroups, to identify whether intensive lifestyle intervention (ILI) is …